Synlogic, Inc. (SYBX)
| Market Cap | 45.84M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -64.54M |
| Shares Out | 70.52M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,185 |
| Open | 0.660 |
| Previous Close | 0.679 |
| Day's Range | 0.643 - 0.700 |
| 52-Week Range | 0.550 - 2.650 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 7.75 (+1,069.81%) |
| Earnings Date | Mar 16, 2023 |
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically abso... [Read more]
Financial Performance
In 2021, Synlogic's revenue was $1.75 million, an increase of 221.83% compared to the previous year's $545,000. Losses were -$60.56 million, 2.35% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SYBX stock is "Buy." The 12-month stock price forecast is $7.75, which is an increase of 1,069.81% from the latest price.
News
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria Presentations included full data f...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
– Podium presentation on Phase 2 phenylketonuria (PKU) data –
Synlogic Announces Participation in Upcoming Investor and Industry Conferences
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the fol...
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted Rare...
Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Synlogic Provides Corporate Update and Outlook for 2023
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its prop...
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today tha...
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its prop...
Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic CAMBRIDGE, Mass. and BOSTON , Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), ...
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update
– Three clinical data readouts across three programs expected in H2 2022 –
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
Expected data in H2 2022 brings Synlogic to three clinical readouts this year
Synlogic Announces Appointment of General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its prop...
Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference
VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its prop...
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprie...
Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update
- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 –
Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its pro...
Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its pro...